Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies.

Area of Science:

• Neurology
• Pediatrics
• Immunology

Background:

• Pediatric-onset multiple sclerosis (POMS) affects individuals under 18, presenting with worse cognitive function and higher disease activity than adult-onset MS.
• Prompt diagnosis and early intervention are critical to modify POMS progression.

Purpose of the Study:

• To review diagnostic criteria for pediatric multiple sclerosis.
• To discuss differential diagnoses for POMS.
• To examine current and emerging therapeutic strategies for POMS.

Main Methods:

• Literature review of diagnostic criteria for pediatric multiple sclerosis.
• Analysis of differential diagnoses relevant to POMS.
• Evaluation of existing clinical trials and real-world data on disease-modifying therapies (DMTs) for POMS.
• Brief overview of ongoing clinical trials and novel therapies for POMS.

Main Results:

• Few DMTs are FDA-approved for pediatric MS, necessitating off-label use supported by real-world evidence.
• Existing evidence supports the effectiveness and safety of certain DMTs in pediatric populations.
• Ongoing research and emerging therapies show promise for POMS treatment.

Conclusions:

• Early recognition and intervention in POMS are vital for improving long-term outcomes.
• Off-label use of DMTs, guided by real-world data, is currently essential for managing POMS.
• Continued research into pediatric-specific therapies is necessary to optimize POMS care.